Cargando…
Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
Primary immunodeficiencies (PIs) are a group of diseases that increase susceptibility to infectious diseases. Few studies have examined the relationship between PI and COVID-19 outcomes. In this study, we used Premier Healthcare Database, which contains information on inpatient discharges, to analyz...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219022/ https://www.ncbi.nlm.nih.gov/pubmed/37240621 http://dx.doi.org/10.3390/jcm12103516 |
_version_ | 1785048911383101440 |
---|---|
author | Drzymalla, Emily Moonesinghe, Ramal Kolor, Katherine Khoury, Muin J. Schieber, Lyna Gundlapalli, Adi V. |
author_facet | Drzymalla, Emily Moonesinghe, Ramal Kolor, Katherine Khoury, Muin J. Schieber, Lyna Gundlapalli, Adi V. |
author_sort | Drzymalla, Emily |
collection | PubMed |
description | Primary immunodeficiencies (PIs) are a group of diseases that increase susceptibility to infectious diseases. Few studies have examined the relationship between PI and COVID-19 outcomes. In this study, we used Premier Healthcare Database, which contains information on inpatient discharges, to analyze COVID-19 outcomes among 853 adult PI and 1,197,430 non-PI patients who visited the emergency department. Hospitalization, intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and death had higher odds in PI patients than in non-PI patients (hospitalization aOR: 2.36, 95% CI: 1.87–2.98; ICU admission aOR: 1.53, 95% CI: 1.19–1.96; IMV aOR: 1.41, 95% CI: 1.15–1.72; death aOR: 1.37, 95% CI: 1.08–1.74), and PI patients spent on average 1.91 more days in the hospital than non-PI patients when adjusted for age, sex, race/ethnicity, and chronic conditions associated with severe COVID-19. Of the largest four PI groups, selective deficiency of the immunoglobulin G subclass had the highest hospitalization frequency (75.2%). This large study of United States PI patients provides real-world evidence that PI is a risk factor for adverse COVID-19 outcomes. |
format | Online Article Text |
id | pubmed-10219022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102190222023-05-27 Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 Drzymalla, Emily Moonesinghe, Ramal Kolor, Katherine Khoury, Muin J. Schieber, Lyna Gundlapalli, Adi V. J Clin Med Article Primary immunodeficiencies (PIs) are a group of diseases that increase susceptibility to infectious diseases. Few studies have examined the relationship between PI and COVID-19 outcomes. In this study, we used Premier Healthcare Database, which contains information on inpatient discharges, to analyze COVID-19 outcomes among 853 adult PI and 1,197,430 non-PI patients who visited the emergency department. Hospitalization, intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and death had higher odds in PI patients than in non-PI patients (hospitalization aOR: 2.36, 95% CI: 1.87–2.98; ICU admission aOR: 1.53, 95% CI: 1.19–1.96; IMV aOR: 1.41, 95% CI: 1.15–1.72; death aOR: 1.37, 95% CI: 1.08–1.74), and PI patients spent on average 1.91 more days in the hospital than non-PI patients when adjusted for age, sex, race/ethnicity, and chronic conditions associated with severe COVID-19. Of the largest four PI groups, selective deficiency of the immunoglobulin G subclass had the highest hospitalization frequency (75.2%). This large study of United States PI patients provides real-world evidence that PI is a risk factor for adverse COVID-19 outcomes. MDPI 2023-05-17 /pmc/articles/PMC10219022/ /pubmed/37240621 http://dx.doi.org/10.3390/jcm12103516 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Drzymalla, Emily Moonesinghe, Ramal Kolor, Katherine Khoury, Muin J. Schieber, Lyna Gundlapalli, Adi V. Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 |
title | Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 |
title_full | Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 |
title_fullStr | Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 |
title_full_unstemmed | Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 |
title_short | Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 |
title_sort | severity outcomes among adult patients with primary immunodeficiency and covid-19 seen in emergency departments, united states, april 2020–august 2021 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219022/ https://www.ncbi.nlm.nih.gov/pubmed/37240621 http://dx.doi.org/10.3390/jcm12103516 |
work_keys_str_mv | AT drzymallaemily severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021 AT moonesingheramal severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021 AT kolorkatherine severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021 AT khourymuinj severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021 AT schieberlyna severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021 AT gundlapalliadiv severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021 |